Advertisement
Review Article| Volume 30, ISSUE 3, P533-543, September 2010

An Update on Cystic Fibrosis Screening

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Boucher R.C.
        Cystic fibrosis.
        in: Harrison T.R. Kasper D.L. Harrison's principles of internal medicine. 16th edition. McGraw-Hill, New York2005: 1543-1546
        • Wapner R.J.
        • Jenkins T.M.
        • Khalek M.
        Prenatal diagnosis of congenital disorders.
        in: Creasy R.K. Resnik R. Iams J.D. Maternal-fetal medicine. Principles and practice. 6th edition. Saunders Elsevier, Philadelphia2009: 221-274
        • American College of Obstetricians and Gynecologists
        Update on carrier screening for cystic fibrosis. ACOG committee opinion #325.
        American College of Obstetricians and Gynecologists, Washington, DC2005
        • Rommens J.M.
        • Iannuzzi M.C.
        • Bat-Sheva K.
        • et al.
        Identification of the cystic fibrosis gene: chromosome walking and jumping.
        Science. 1989; 245: 1059-1065
        • Riordan J.R.
        • Rommens J.M.
        • Bat-Sheva K.
        • et al.
        Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
        Science. 1989; 245: 1066-1072
        • Kerem B.
        • Rommens J.M.
        • Buchanan J.A.
        • et al.
        Identification of the cystic fibrosis gene: genetic analysis.
        Science. 1989; 245: 1073-1080
        • Nussbaum R.L.
        • McInnes R.R.
        • Willard H.L.
        The molecular, biochemical, and cellular basis of genetic disease.
        in: Thompson & Thompson genetics in medicine. 7th edition. Saunders Elsevier, Philadelphia2007: 364-367
        • Tsui L- C.
        Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium.
        Hum Mutat. 1992; 1: 197-203
        • The Cystic Fibrosis Genotype-Phenotype Consortium
        Correlation between genotype and phenotype in patients with cystic fibrosis.
        N Engl J Med. 1993; 329: 1308-1313
        • Osborne L.
        • Santis G.
        • Schwarz M.
        • et al.
        Incidence and expression of the N1303K mutation of the cystic fibrosis (CFTR) gene.
        Hum Genet. 1992; 89: 653-658
        • Gasparini P.
        • Borgo G.
        • Mastella G.
        • et al.
        Nine cystic fibrosis patients homozygous for the CFTR nonsense mutation R1162X have mild or moderate lung disease.
        J Med Genet. 1992; 29: 558-562
        • Collaco J.M.
        • Vanscoy L.
        • Bremer L.
        • et al.
        Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease.
        JAMA. 2009; 299: 417-424
        • Campbell III, P.W.
        • Parker R.A.
        • Roberts B.T.
        • et al.
        Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the F508 deletion.
        J Pediatr. 1992; 120: 261-264
        • Drumm M.L.
        • Konstan M.W.
        • Schluchter M.D.
        • et al.
        Genetic modifiers of lung disease in cystic fibrosis.
        N Engl J Med. 2005; 353: 1443-1453
        • Chillon M.
        • Casals T.
        • Mercier B.
        • et al.
        Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens.
        N Engl J Med. 1995; 332: 1475-1480
        • Gervais R.
        • Dumur V.
        • Rigot M.-M.
        • et al.
        High frequency of the R117H cystic fibrosis mutation in patients with congenital absence of the vas deferens.
        N Engl J Med. 1993; 328: 446-447
        • Kiesewetter S.
        • Macek M.
        • Davis C.
        • et al.
        A mutation in CFTR produces different phenotypes depending on chromosomal background.
        Nat Genet. 1993; 5: 274-277
        • Shoshani T.
        • Augarten A.
        • Gazit E.
        • et al.
        Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease.
        Am J Hum Genet. 1992; 50: 222-228
        • Sugarman E.A.
        • Rohlfs E.M.
        • Silverman L.M.
        • et al.
        CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations.
        Genet Med. 2004; 6: 392-399
        • Monaghan K.G.
        • Bluhm D.
        • Phillips M.
        • et al.
        Preconception and prenatal cystic fibrosis carrier screening of African Americans reveals unanticipated frequencies for specific mutations.
        Genet Med. 2004; 6: 141-144
        • NIH Consensus Development Conference Statement
        Genetic testing for cystic fibrosis. April 14–16, 1997.
        Arch Intern Med. 1999; 159: 1529-1539
        • Grody W.W.
        • Cutting G.R.
        • Klinger K.W.
        • et al.
        Laboratory standards and guidelines for population-based cystic fibrosis carrier screening.
        Genet Med. 2001; 3: 149-154
        • Watson M.S.
        • Cutting G.R.
        • Desnick R.J.
        • et al.
        Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel.
        Genet Med. 2004; 6: 387-391
        • Dork T.
        • Dworniczak B.
        • Aulehis-Schotz C.
        • et al.
        Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens.
        Hum Genet. 1997; 100: 365-377
        • Richards C.S.
        • Bradley L.A.
        • Amos J.
        • et al.
        Standards and guidelines for CFTR mutation testing.
        Genet Med. 2002; 4: 379-391
        • Wald N.J.
        Couple screening for cystic fibrosis.
        Lancet. 1991; 338: 1318-1319
        • Miedzybrodzka Z.H.
        • Hall M.H.
        • Mollison J.
        • et al.
        Antenatal screening for carriers of cystic fibrosis: randomized trial of stepwise v couple screening.
        BMJ. 1995; 310: 353-357
        • Norton M.F.
        Genetics and prenatal diagnosis.
        in: Callen P.W. Ultrasonography in obstetrics and gynecology. 5th edition. Saunders Elsevier, Philadelphia2008: 26-59
        • Nyberg D.A.
        • Dubinsky T.
        • Resta R.G.
        • et al.
        Echogenic fetal bowel during the second trimester: clinical importance.
        Radiology. 1993; 188: 527-531
        • Dicke J.M.
        • Crane J.P.
        Sonographically detected hyperechoic fetal bowel: significance and implications for pregnancy management.
        Obstet Gynecol. 1992; 80: 778-782
        • Sepulveda W.
        • Hollingsworth J.
        • Bower S.
        • et al.
        Fetal hyperechogenic bowel following intra-amniotic bleeding.
        Obstet Gynecol. 1994; 83: 947-950
        • Boue A.
        • Muller F.
        • Nezelof C.
        • et al.
        Prenatal diagnosis in 200 pregnancies with a 1 in 4 risk of cystic fibrosis.
        Hum Genet. 1986; 74: 288-297
        • Sepulveda W.
        • Leung K.Y.
        • Robertson M.E.
        • et al.
        Prevalence of cystic fibrosis mutations in pregnancies with fetal echogenic bowel.
        Obstet Gynecol. 1996; 87: 103-106
        • Muller F.
        • Simon-Bouy B.
        • Girodon E.
        • et al.
        Predicting the risk of cystic fibrosis with abnormal ultrasound signs of fetal bowel: results of a French Molecular Collaborative study based on 641 prospective cases.
        Am J Med Genet. 2002; 110: 109-115
        • Odibo A.O.
        • Gray D.L.
        • Dicke J.M.
        • et al.
        Revisiting the fetal loss rate after second-trimester genetic amniocentesis.
        Obstet Gynecol. 2008; 111: 589-595
        • Odibo A.O.
        • Dicke J.M.
        • Gray D.L.
        • et al.
        Evaluating the rate and risk factors for fetal loss after chorionic villus sampling.
        Obstet Gynecol. 2008; 112: 813-819
        • Ao A.
        • Ray P.
        • Harper J.
        • et al.
        Clinical experience with preimplantation genetic diagnosis of cystic fibrosis (ΔF508).
        Prenat Diagn. 1996; 16: 137-142
        • Gutierrez-Mateo C.
        • Sanchez-Garcia J.F.
        • Fischer J.
        • et al.
        Preimplantation genetic diagnosis of single gene disorders: experience with more than 200 cycles conducted by a reference laboratory in the United States.
        Fertil Steril. 2009; 92: 1544-1556
        • Handyside A.H.
        • Lesko J.H.
        • Tarin J.J.
        • et al.
        Birth of a normal girl after in vitro fertilization and preimplantation diagnostic testing for cystic fibrosis.
        N Engl J Med. 1992; 327: 905-909
        • Davis L.B.
        • Champion S.J.
        • Fair S.O.
        • et al.
        A cost-benefit analysis of preimplantation genetic diagnosis for carrier couples of cystic fibrosis.
        Fertil Steril. 2010; 93: 1793-1804